

EudraCT number: 2020-004964-25

IMP name/code: izokibep (previous ABY-035)

Sponsor Protocol Number: ABY-035-203

Title of the trial: A phase 2 trial of the efficacy and safety of the interleukin-17A inhibitor ABY-035 in the treatment and prevention of relapse/recurrence of non-infectious intermediate, posterior or pan-uveitis (LINNAEA)

The above-mentioned clinical trial was ended prematurely on 2022-01-31. No subjects were recruited in any European Union (EU)/European Economic Area (EEA) countries.

The reason the clinical trial was ended prematurely was that the sponsor, Affibody AB, had entered into an agreement with a partner company, ACELYRIN, INC., for the development of izokibep (ABY-035). In this context, the sponsorship for the United States part of the clinical trial ABY-035-203 (LINNAEA) was transferred to ACELYRIN, INC. The clinical trial ABY-035-203 (LINNAEA) will only be conducted in the United States, therefore, it has been prematurely ended in all concerned EU countries.